Paul Hoelscher - Horizon Pharma CFO and Executive VP of Fin.
| HZNPDelisted Stock | USD 100.40 0.13 0.13% |
CFO
Mr. Paul W. Hoelscher is Chief Financial Officer, Executive Vice President of the Company. Mr. Hoelscher has served as our executive vice president, chief financial officer since October 2014. Previously, Mr. Hoelscher was our executive vice president, finance from June 2014 through September 2014. Prior to joining Horizon Pharma, Mr. Hoelscher served as senior vice president, financetreasury and corporate development of OfficeMax, Inc., from August 2013 to May 2014, and as vice president, financetreasury and corporate development of OfficeMax from August 2012 to July 2013. From May 2011 to May 2012, Mr. Hoelscher served as vice president, finance integration of Alberto Culver Company, a beauty care company which was acquired by Unilever in 2011. Prior to that, Mr. Hoelscher served as vice president, international finance and treasurer from 2010 to May 2011 and vice president, corporate controller from 2004 to 2010. Mr. Hoelscher also served in various positions in the audit practice at KPMG LLP from 1986 to 1993 and currently serves as chair of the board of trustees of the Illinois Chapter of the Leukemia and Lymphoma Society since 2014.
| Age | 58 |
| Tenure | 10 years |
| Phone | 353 1 772 2100 |
| Web | https://www.horizontherapeutics.com |
Horizon Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 5 records | CFO Age | ||
| Scott Reents | AbbVie Inc | 56 | |
| Peter Griffith | Amgen Inc | 65 | |
| Harry Kirsch | Novartis AG ADR | 59 | |
| Lucas Montarce | Eli Lilly and | 47 | |
| Joseph CPA | Johnson Johnson | 57 | |
Management Performance
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 |
Horizon Pharma PLC Leadership Team
Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jane Gonnerman, Office Staff | ||
| Sean JD, Exec Counsel | ||
| Timothy Walbert, Chairman, CEO and Pres | ||
| Tina Ventura, Senior Vice President Investor Relations | ||
| Patrick McIlvenny, VP Officer | ||
| Paul Hoelscher, CFO and Executive VP of Fin. | ||
| FACP FACP, Ex Officer | ||
| Andy Pasternak, Ex Officer | ||
| Aaron Cox, Exec CFO | ||
| Geoffrey Curtis, Senior Vice President - Corporate Communications |
Horizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X |
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Horizon Stock
| 0.82 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.75 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.74 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.68 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.67 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
The ability to find closely correlated positions to Horizon Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Horizon Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Horizon Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Horizon Pharma PLC to buy it.
The correlation of Horizon Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Horizon Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Horizon Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Horizon Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |